Andrew P. Mazar

Overview

Best Publications

• Structure of Human Urokinase Plasminogen Activator in Complex with Its Receptor

  Qing Huai;Andrew P. Mazar;Alice Kuo;Graham C. Parry

  353
  Citations

• Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling

  Jose C. Juarez;Mari Manuia;Mark E. Burnett;Oscar Betancourt

  304
  Citations

• Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.

  Shafaat A. Rabbani;Andrew P. Mazar;Suzanne M. Bernier;Mahmudul Haq

  300
  Citations

• Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion

  Hilary A. Kenny;Chun Yi Chiang;Erin A. White;Elizabeth M. Schryver

  296
  Citations

• Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice

  Oliver Stoeltzing;Wenbiao Liu;Niels Reinmuth;Fan Fan

  273
  Citations

• Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor.

  Robert W. Colman;Robin A. Pixley;Syeda Najamunnisa;Wuyi Yan

  270
  Citations

• Urokinase-type Plasminogen Activator Receptor (CD87) Is a Ligand for Integrins and Mediates Cell-Cell Interaction

  Takehiko Tarui;Andrew P. Mazar;Douglas B. Cines;Yoshikazu Takada

  250
  Citations

• The role of the plasminogen activation system in angiogenesis and metastasis.

  Shafaat A. Rabbani;Andrew P. Mazar

  244
  Citations

• The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis.

  Andrew P. Mazar;Jack Henkin;Ronald H. Goldfarb

  242
  Citations

• AN AMINO-TERMINAL FRAGMENT OF UROKINASE ISOLATED FROM A PROSTATE CANCER CELL LINE (PC-3) IS MITOGENIC FOR OSTEOBLAST-LIKE CELLS

  Shafast A. Rabbani;Johanne Desjardins;Alexander W. Bell;Denis Banville

  234
  Citations

• A non–RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo

  Parisa Khalili;Ani Arakelian;Gaoping Chen;Marian L. Plunkett

  231
  Citations

• Targeting SOD1 reduces experimental non–small-cell lung cancer

  Andrea Glasauer;Laura A. Sena;Lauren P. Diebold;Andrew P. Mazar

  205
  Citations

• Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours.

  M E Cianfrocca;K A Kimmel;J Gallo;T Cardoso

  197
  Citations

• Targeting of Urokinase Plasminogen Activator Receptor in Human Pancreatic Carcinoma Cells Inhibits c-Met– and Insulin-like Growth Factor-I Receptor–Mediated Migration and Invasion and Orthotopic Tumor Growth in Mice

  Todd W. Bauer;Wenbiao Liu;Fan Fan;Ernest R. Camp

  195
  Citations

• Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines.

  Naseema M. Hoosein;Douglas D. Boyd;William J. Hollas;Andrew Mazar

  189
  Citations

• Copper Binding by Tetrathiomolybdate Attenuates Angiogenesis and Tumor Cell Proliferation through the Inhibition of Superoxide Dismutase 1

  Jose C. Juarez;Oscar Betancourt;Steven R. Pirie-Shepherd;Xiaojun Guan

  185
  Citations

• Urokinase Plasminogen Activator Receptor Choreographs Multiple Ligand Interactions: Implications for Tumor Progression and Therapy

  Andrew P. Mazar

  177
  Citations

• A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo

  Yongjing Guo;Abd Al-Roof Higazi;Ani Arakelian;Bruce S. Sachais

  162
  Citations

• Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer

  Amy Walz;Andrey Ugolkov;Sunandana Chandra;Alan Kozikowski

  162
  Citations

• Differential Angiogenic Regulation of Experimental Colitis

  John H. Chidlow;Will Langston;James J.M. Greer;Dmitry Ostanin

  159
  Citations